Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection

Current Opinion in Microbiology

Volumn 16, Issue 1, 2013, Pages 100-107

  Ulett, Glen C ^a   Totsika, Makrina ^b   Schaale, Kolja ^b   Carey, Alison J ^a   Sweet, Matthew J ^b   Schembri, Mark A ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLOOXYGENASE 2; CYTOTOXIC NECROTIZING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PURINERGIC P2Y RECEPTOR; TOLL LIKE RECEPTOR 4; VIRULENCE FACTOR;

BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CYSTITIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; IMMUNITY, INNATE; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI; VIRULENCE FACTORS;

ESCHERICHIA COLI;

EID: 84875812043     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.01.005     Document Type: Review

References (82)

1. Nielubowicz G.R., Mobley H.L. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010, 7:430-441.
2. Alteri C.J., Smith S.N., Mobley H.L. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog 2009, 5:e1000448.
3. Norton J.P., Mulvey M.A. Toxin-antitoxin systems are important for niche-specific colonization and stress resistance of uropathogenic Escherichia coli. PLoS Pathog 2012, 8:e1002954.
4. Busch A., Waksman G. Chaperone-usher pathways: diversity and pilus assembly mechanism. Philos Trans R Soc Lond B: Biol Sci 2012, 367:1112-1122.
5. Sokurenko E.V., Vogel V., Thomas W.E. Catch-bond mechanism of force-enhanced adhesion: counterintuitive, elusive, but ... widespread?. Cell Host Microbe 2008, 3:314-323.
6. Ashkar A.A., Mossman K.L., Coombes B.K., Gyles C.L., Mackenzie R. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog 2008, 4:e1000233.
7. Korea C.G., Ghigo J.M., Beloin C. The sweet connection: solving the riddle of multiple sugar-binding fimbrial adhesins in Escherichia coli: multiple E. coli fimbriae form a versatile arsenal of sugar-binding lectins potentially involved in surface-colonisation and tissue tropism. Bioessays 2011, 33:300-311.
8. Kai-Larsen Y., Luthje P., Chromek M., Peters V., Wang X., Holm A., Kadas L., Hedlund K.O., Johansson J., Chapman M.R., et al. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog 2010, 6:e1001010.
9. Allsopp L.P., Totsika M., Tree J.J., Ulett G.C., Mabbett A.N., Wells T.J., Kobe B., Beatson S.A., Schembri M.A. UpaH is a newly identified autotransporter protein that contributes to biofilm formation and bladder colonization by uropathogenic Escherichia coli CFT073. Infect Immun 2010, 78:1659-1669.
10. Ulett G.C., Valle J., Beloin C., Sherlock O., Ghigo J.M., Schembri M.A. Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract. Infect Immun 2007, 75:3233-3244.
11. Vigil P.D., Wiles T.J., Engstrom M.D., Prasov L., Mulvey M.A., Mobley H.L. The repeat-in-toxin family member TosA mediates adherence of uropathogenic Escherichia coli and survival during bacteremia. Infect Immun 2012, 80:493-505.
12. Lane M.C., Alteri C.J., Smith S.N., Mobley H.L. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A 2007, 104:16669-16674.
13. Dhakal B.K., Mulvey M.A. The UPEC pore-forming toxin alpha-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways. Cell Host Microbe 2012, 11:58-69.
14. Dhakal B.K., Kulesus R.R., Mulvey M.A. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest 2008, 38(Suppl. 2):2-11.
15. Smith Y.C., Rasmussen S.B., Grande K.K., Conran R.M., O'Brien A.D. Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24hours after intraurethral inoculation of mice. Infect Immun 2008, 76:2978-2990.
16. Wiles T.J., Bower J.M., Redd M.J., Mulvey M.A. Use of zebrafish to probe the divergent virulence potentials and toxin requirements of extraintestinal pathogenic Escherichia coli. PLoS Pathog 2009, 5:e1000697.
17. Henderson J.P., Crowley J.R., Pinkner J.S., Walker J.N., Tsukayama P., Stamm W.E., Hooton T.M., Hultgren S.J. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog 2009, 5:e1000305.
18. Watts R.E., Totsika M., Challinor V.L., Mabbett A.N., Ulett G.C., De Voss J.J., Schembri M.A. Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli. Infect Immun 2012, 80:333-344.
19. Roos V., Ulett G.C., Schembri M.A., Klemm P. The asymptomatic bacteriuria Escherichia coli strain 83972 outcompetes uropathogenic E. coli strains in human urine. Infect Immun 2006, 74:615-624.
20. Chaturvedi K.S., Hung C.S., Crowley J.R., Stapleton A.E., Henderson J.P. The siderophore yersiniabactin binds copper to protect pathogens during infection. Nat Chem Biol 2012.
21. Garcia E.C., Brumbaugh A.R., Mobley H.L. Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun 2011, 79:1225-1235.
22. Hood M.I., Skaar E.P. Nutritional immunity: transition metals at the pathogen-host interface. Nat Rev Microbiol 2012, 10:525-537.
23. Mobley H.L., Green D.M., Trifillis A.L., Johnson D.E., Chippendale G.R., Lockatell C.V., Jones B.D., Warren J.W. Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun 1990, 58:1281-1289.
24. Garofalo C.K., Hooton T.M., Martin S.M., Stamm W.E., Palermo J.J., Gordon J.I., Hultgren S.J. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun 2007, 75:52-60.
25. Chen S.L., Hung C.S., Xu J., Reigstad C.S., Magrini V., Sabo A., Blasiar D., Bieri T., Meyer R.R., Ozersky P., et al. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci U S A 2006, 103:5977-5982.
26. Schwartz D.J., Chen S.L., Hultgren S.J., Seed P.C. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun 2011, 79:4250-4259.
27. Walters M.S., Lane M.C., Vigil P.D., Smith S.N., Walk S.T., Mobley H.L. Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection. mBio 2012, 3.
28. Totsika M., Beatson S.A., Sarkar S., Phan M.D., Petty N.K., Bachmann N., Szubert M., Sidjabat H.E., Paterson D.L., Upton M., et al. Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS ONE 2011, 6:e26578.
29. Hannan T.J., Totsika M., Mansfield K.J., Moore K.H., Schembri M.A., Hultgren S.J. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 2012, 36:616-648.
30. Chen S.L., Hung C.S., Pinkner J.S., Walker J.N., Cusumano C.K., Li Z., Bouckaert J., Gordon J.I., Hultgren S.J. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci U S A 2009, 106:22439-22444.
31. Anderson G.G., Goller C.C., Justice S., Hultgren S.J., Seed P.C. Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infect Immun 2010, 78:963-975.
32. Justice S.S., Hunstad D.A., Seed P.C., Hultgren S.J. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Natl Acad Sci U S A 2006, 103:19884-19889.
33. Rosen D.A., Hooton T.M., Stamm W.E., Humphrey P.A., Hultgren S.J. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007, 4:e329.
34. Hadjifrangiskou M., Gu A.P., Pinkner J.S., Kostakioti M., Zhang E.W., Greene S.E., Hultgren S.J. Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. J Bacteriol 2012, 194:6195-6205.
35. Mysorekar I.U., Hultgren S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 2006, 103:14170-14175.
36. Bokil N.J., Totsika M., Carey A.J., Stacey K.J., Hancock V., Saunders B.M., Ravasi T., Ulett G.C., Schembri M.A., Sweet M.J. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages. Immunobiology 2011, 216:1164-1171.
37. Hannan T.J., Mysorekar I.U., Hung C.S., Isaacson-Schmid M.L., Hultgren S.J. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010, 6.
38. Frendeus B., Wachtler C., Hedlund M., Fischer H., Samuelsson P., Svensson M., Svanborg C. Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol Microbiol 2001, 40:37-51.
39. Duell B.L., Carey A.J., Tan C.K., Cui X., Webb R.I., Totsika M., Schembri M.A., Derrington P., Irving-Rodgers H., Brooks A.J., et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 2012, 188:781-792.
40. Tan C.K., Carey A.J., Cui X., Webb R.I., Ipe D., Crowley M., Cripps A.W., Benjamin W.H., Ulett K.B., Schembri M.A., et al. Genome-wide mapping of cystitis due to Streptococcus agalactiae and Escherichia coli in mice identifies a unique bladder transcriptome that signifies pathogen-specific antimicrobial defense against urinary tract infection. Infect Immun 2012, 80:3145-3160.
41. Mysorekar I.U., Mulvey M.A., Hultgren S.J., Gordon J.I. Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem 2002, 277:7412-7419.
42. Marschall J., Zhang L., Foxman B., Warren D.K., Henderson J.P. Both host and pathogen factors predispose to Escherichia coli urinary-source bacteremia in hospitalized patients. Clin Infect Dis 2012, 54:1692-1698.
43. Rudick C.N., Billips B.K., Pavlov V.I., Yaggie R.E., Schaeffer A.J., Klumpp D.J. Host-pathogen interactions mediating pain of urinary tract infection. J Infect Dis 2010, 201:1240-1249.
44. Rudick C.N., Jiang M., Yaggie R.E., Pavlov V.I., Done J., Heckman C.J., Whitfield C., Schaeffer A.J., Klumpp D.J. O-antigen modulates infection-induced pain states. PLoS ONE 2012, 7:e41273.
45. Rudick C.N., Berry R.E., Johnson J.R., Johnston B., Klumpp D.J., Schaeffer A.J., Thumbikat P. Uropathogenic Escherichia coli induces chronic pelvic pain. Infect Immun 2011, 79:628-635.
46. Ragnarsdottir B., Lutay N., Gronberg-Hernandez J., Koves B., Svanborg C. Genetics of innate immunity and UTI susceptibility. Nat Rev Urol 2011, 8:449-468.
47. Suhs K.A., Marthaler B.R., Welch R.A., Hopkins W.J. Lack of association between the Tlr4 (Lpsd/Lpsd) genotype and increased susceptibility to Escherichia coli bladder infections in female C3H/HeJ mice. mBio 2011, 2. e00094-00011.
48. Hertting O., Holm A., Luthje P., Brauner H., Dyrdak R., Jonasson A.F., Wiklund P., Chromek M., Brauner A. Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder. PLoS ONE 2010, 5:e15580.
49. Polgarova K., Luthje P., Cerami A., Brauner A. The erythropoietin analogue ARA290 modulates the innate immune response and reduces Escherichia coli invasion into urothelial cells. FEMS Immunol Med Microbiol 2011, 62:190-196.
50. Save S., Persson K. Extracellular ATP and P2Y receptor activation induce a proinflammatory host response in the human urinary tract. Infect Immun 2010, 78:3609-3615.
51. Erman A., Lakota K., Mrak-Poljsak K., Blango M.G., Krizan-Hergouth V., Mulvey M.A., Sodin-Semrl S., Veranic P. Uropathogenic Escherichia coli induces serum amyloid a in mice following urinary tract and systemic inoculation. PLoS ONE 2012, 7:e32933.
52. De Santo C., Arscott R., Booth S., Karydis I., Jones M., Asher R., Salio M., Middleton M., Cerundolo V. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010, 11:1039-1046.
53. Sivick K.E., Schaller M.A., Smith S.N., Mobley H.L. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J Immunol 2010, 184:2065-2075.
54. Ingersoll M.A., Kline K.A., Nielsen H.V., Hultgren S.J. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008, 10:2568-2578.
55. Haraoka M., Hang L., Frendeus B., Godaly G., Burdick M., Strieter R., Svanborg C. Neutrophil recruitment and resistance to urinary tract infection. J Infect Dis 1999, 180:1220-1229.
56. Hang L., Haraoka M., Agace W.W., Leffler H., Burdick M., Strieter R., Svanborg C. Macrophage inflammatory protein-2 is required for neutrophil passage across the epithelial barrier of the infected urinary tract. J Immunol 1999, 162:3037-3044.
57. Duell B.L., Tan C.K., Carey A.J., Wu F., Cripps A.W., Ulett G.C. Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol 2012, 64:295-313.
58. Rubino S.J., Geddes K., Girardin S.E. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol 2012, 33:112-118.
59. Karlsson M., Scherbak N., Reid G., Jass J. Lactobacillus rhamnosus GR-1 enhances NF-kappaB activation in Escherichia coli-stimulated urinary bladder cells through TLR4. BMC Microbiol 2012, 12:15.
60. Fischer H., Lutay N., Ragnarsdottir B., Yadav M., Jonsson K., Urbano A., Al Hadad A., Ramisch S., Storm P., Dobrindt U., et al. Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection. PLoS Pathog 2010, 6:e1001109.
61. Ulett G.C., Webb R.I., Ulett K.B., Cui X., Benjamin W.H., Crowley M., Schembri M.A. Group B Streptococcus (GBS) urinary tract infection involves binding of GBS to bladder uroepithelium and potent but GBS-specific induction of interleukin 1alpha. J Infect Dis 2010, 201:866-870.
62. Billips B.K., Schaeffer A.J., Klumpp D.J. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder. Infect Immun 2008, 76:3891-3900.
63. Cirl C., Wieser A., Yadav M., Duerr S., Schubert S., Fischer H., Stappert D., Wantia N., Rodriguez N., Wagner H., et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008, 14:399-406.
64. Yadav M., Zhang J., Fischer H., Huang W., Lutay N., Cirl C., Lum J., Miethke T., Svanborg C. Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS Pathog 2010, 6:e1001120.
65. Wang Z., Humphrey C., Frilot N., Wang G., Nie Z., Moniri N.H., Daaka Y. Dynamin2- and endothelial nitric oxide synthase-regulated invasion of bladder epithelial cells by uropathogenic Escherichia coli. J Cell Biol 2011, 192:101-110.
66. Hilbert D.W., Paulish-Miller T.E., Tan C.K., Carey A.J., Ulett G.C., Mordechai E., Adelson M.E., Gygax S.E., Trama J.P. Clinical Escherichia coli isolates utilize alpha-hemolysin to inhibit in vitro epithelial cytokine production. Microbes Infect 2012, 14:628-638.
67. Wang C., Mendonsa G.R., Symington J.W., Zhang Q., Cadwell K., Virgin H.W., Mysorekar I.U. Atg16L1 deficiency confers protection from uropathogenic Escherichia coli infection in vivo. Proc Natl Acad Sci U S A 2012, 109:11008-11013.
68. Saitoh T., Fujita N., Jang M.H., Uematsu S., Yang B.G., Satoh T., Omori H., Noda T., Yamamoto N., Komatsu M., et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008, 456:264-268.
69. Chen T.C., Tsai J.P., Huang H.J., Teng C.C., Chien S.J., Kuo H.C., Huang W.S., Chen C.N. Regulation of cyclooxygenase-2 expression in human bladder epithelial cells infected with type I fimbriated uropathogenic E. coli. Cell Microbiol 2011, 13:1703-1713.
70. Loughman J.A., Hunstad D.A. Induction of indoleamine 2,3-dioxygenase by uropathogenic bacteria attenuates innate responses to epithelial infection. J Infect Dis 2012, 205:1830-1839.
71. Cesario A., Rocca B., Rutella S. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem 2011, 18:2263-2271.
72. Totsika M., Beatson S.A., Holden N., Gally D.L. Regulatory interplay between pap operons in uropathogenic Escherichia coli. Mol Microbiol 2008, 67:996-1011.
73. Hawn T.R., Scholes D., Li S.S., Wang H., Yang Y., Roberts P.L., Stapleton A.E., Janer M., Aderem A., Stamm W.E., et al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS ONE 2009, 4:e5990.
74. Tabel Y., Berdeli A., Mir S. Association of TLR2 gene Arg753Gln polymorphism with urinary tract infection in children. Int J Immunogenet 2007, 34:399-405.
75. Karoly E., Fekete A., Banki N.F., Szebeni B., Vannay A., Szabo A.J., Tulassay T., Reusz G.S. Heat shock protein 72 (HSPA1B) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Pediatr Res 2007, 61:371-374.
76. Yin X., Hou T., Liu Y., Chen J., Yao Z., Ma C., Yang L., Wei L. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS ONE 2010, 5:e14223.
77. Ragnarsdottir B., Jonsson K., Urbano A., Gronberg-Hernandez J., Lutay N., Tammi M., Gustafsson M., Lundstedt A.C., Leijonhufvud I., Karpman D., et al. Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS ONE 2010, 5:e10734.
78. Andersen-Nissen E., Hawn T.R., Smith K.D., Nachman A., Lampano A.E., Uematsu S., Akira S., Aderem A. Cutting edge: Tlr5-/- mice are more susceptible to Escherichia coli urinary tract infection. J Immunol 2007, 178:4717-4720.
79. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., Ghosh S. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004, 303:1522-1526.
80. Hidmark A., von Saint Paul A., Dalpke A.H. Cutting edge: TLR13 is a receptor for bacterial RNA. J Immunol 2012, 189:2717-2721.
81. Barber G.N. Cytoplasmic DNA innate immune pathways. Immunol Rev 2011, 243:99-108.
82. Franchi L., Munoz-Planillo R., Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012, 13:325-332.